Invitrogen™ Lirilumab Recombinant Human Monoclonal Antibody

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Lirilumab, also known as IPH2102 or BMS-986015, is a fully human IgG4 monoclonal antibody targeting inhibitory killer-cell immunoglobulin-like receptors (KIRs), notably KIR2DL1, KIR2DL2, and KIR2DL3, as well as activating KIR2DS1 and KIR2DS2. The structure of lirilumab includes the variable domains which bind to a conformational epitope on domain 1 of KIR2DL3. This binding does not significantly alter the structure of KIR2DL3 in comparison to its unbound form. Lirilumab's binding epitope overlaps with the HLA binding site, which influences the clinical efficacy of the drug as variations in this epitope among patients may impact its effectiveness. Functionally, lirilumab blocks inhibitory KIRs, thereby enhancing NK cell activity against tumor cells. This mechanism underlies its investigation in clinical trials for hematologic and solid malignancies, evaluating its efficacy both as a monotherapy and in combination with other agents such as azacitidine.